Bioxcel Therapeutics (BTAI)
$2.61
Insights on Bioxcel Therapeutics
Increasing Revenue
Revenue is up for the last 2 quarters, 341.0K → 376.0K (in $), with an average increase of 9.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -53.51M → -22.25M (in $), with an average increase of 66.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 140.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 332.1%
Performance
- $2.56$2.72$2.61
1.92%
Downside
Day's Volatility :5.88%
Upside
4.04%
- $1.91$29.56$2.61
26.82%
Downside
52 Weeks Volatility :93.54%
Upside
91.17%
Returns
| Period | Bioxcel Therapeutics | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -21.15% | 0.5% | 0.0% |
6 Months | -13.0% | 11.7% | 0.0% |
1 Year | -87.54% | 6.2% | 2.2% |
3 Years | -92.64% | 13.5% | -23.0% |
Highlights
Market Capitalization | 82.9M |
Book Value | - $1.89 |
Earnings Per Share (EPS) | -6.15 |
Wall Street Target Price | 10.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -5285.9% |
Return On Assets TTM | -74.95% |
Return On Equity TTM | -1766.94% |
Revenue TTM | 1.4M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 57.99999999999999% |
Gross Profit TTM | 355.0K |
EBITDA | -167.3M |
Diluted Eps TTM | -6.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.76 |
EPS Estimate Next Year | -1.99 |
EPS Estimate Current Quarter | -0.91 |
EPS Estimate Next Quarter | -0.97 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 302.3%
Technicals Summary
Sell
Neutral
Buy
Bioxcel Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Bioxcel Therapeutics | -8.74% | -13.0% | -87.54% | -92.64% | -76.14% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Bioxcel Therapeutics | NA | NA | NA | -2.76 | -17.67 | -0.75 | NA | -1.89 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Bioxcel Therapeutics | Buy | $82.9M | -76.14% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
FMR Inc
8.24%BlackRock Inc
4.49%Vanguard Group Inc
3.56%Ameriprise Financial Inc
1.77%Adage Capital Partners Gp LLC
1.52%Geode Capital Management, LLC
1.47%
Corporate Announcements
Bioxcel Therapeutics Earnings
Bioxcel Therapeutics’s price-to-earnings ratio stands at None
Read More
Company Information
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Organization | Bioxcel Therapeutics |
Employees | 74 |
CEO | Dr. Vimal D. Mehta Ph.D. |
Industry | Health Technology |
